Skip to main content
Season 3 ends in 25 d 11:42:40 $2,000 10,000 pts = 1 month Premium
Health & Medicine

Stopping Statins After 70: What the STREAM Trial Found

Published 11 min read
Open the post and read it to claim 30 points
A weekly seven-day pill organiser with one tablet per day beside reading glasses and a glass of water, illustrating stopping statins after 70 and the STREAM trial

Sign in and earn +30 points by reading this

Read to the end, wait a few seconds, then tap the claim button below.

In short

As of 13 November 2026, the STREAM trial, published in the New England Journal of Medicine on 7 November, found that stopping statins in adults aged 70 or older with no known heart disease met its noninferiority goal at two years [1]. More people who stopped had a heart attack, stroke or died [1].

Key takeaways

  1. STREAM randomly assigned 1,880 adults aged 70 or older, with at least two chronic conditions and no known cardiovascular disease, to stop or continue statins [1].
  2. Stopping was noninferior to continuing on the trial's main measure at two years: event-free time differed by 2.0 weeks, inside the prespecified margin of 5.2 weeks [1].
  3. Over a median of 103 weeks, 12.7% of those who stopped and 9.2% of those who continued had a heart attack, ischaemic stroke or died [1].
  4. Lead investigator Nicolas Rodondi estimated one additional major event or death over two years for every 40 people who stop, and stressed shared decision-making [2][3][6].
  5. A secondary analysis found no difference in pain, quality of life, falls or sarcopenia (muscle loss) risk between groups [2][6].
  6. The results apply only to statins taken for primary prevention; they say nothing about people who have already had a heart attack or stroke [1].
On this page 10 sections
  1. What did the STREAM trial find about stopping statins?
  2. Who was in the STREAM trial?
  3. Why was stopping statins after 70 an open question?
  4. How much did heart risk rise after stopping statins?
  5. Did people feel better after stopping statins?
  6. What does STREAM not show?
  7. Common mistakes
  8. Frequently asked questions
  9. Glossary
  10. Sources

What did the STREAM trial find about stopping statins?

STREAM found that stopping statins in adults aged 70 or older without known heart disease was "noninferior" to continuing them at two years, meaning it met a prespecified statistical margin, but cardiovascular events and deaths were more frequent after stopping [1][2]. The trial was presented at the American Heart Association's Scientific Sessions and published in the New England Journal of Medicine on 7 November 2026 [1][2].

  • Main measure: the difference in average event-free time over two years was −2.0 weeks for the stopping group (95% confidence interval −3.7 to −0.3 weeks), within the noninferiority margin of −5.2 weeks [1].
  • Events over full follow-up: over a median of 103 weeks, 119 (12.7%) in the stopping group and 87 (9.2%) in the continuing group had such an event [1].
  • Serious adverse events: at least one occurred in 43.0% of the stopping group and 39.8% of the continuing group [1].

"Noninferior" does not mean "equally safe" in everyday language. It means the loss of event-free time stayed smaller than the threshold the researchers set in advance as acceptable [1].

A 3D illustration of an artery with a cholesterol plaque, representing heart attack and stroke risk in the STREAM statin trial
Statins lower cholesterol to reduce the risk of plaque-related heart attacks and strokes.

Who was in the STREAM trial?

STREAM enrolled 1,880 adults aged 70 or older who took statins for primary prevention, had at least two chronic conditions and had no known cardiovascular disease [1][2]. Primary prevention means taking a statin to lower the risk of a first heart attack or stroke, not after one has already happened.

  • Size and groups: 938 were assigned to stop statins and other lipid-lowering drugs, and 942 to continue [1].
  • Age and sex: the average age was 77.5 years, and 46.9% were women [1].
  • Where: 24 centres in Switzerland, France and the Netherlands, according to the AHA and TCTMD [2][6].
  • Design: randomised and open-label, so participants and doctors knew who had stopped [1].
  • Outcome measured: a combination of non-fatal heart attack, non-fatal ischaemic stroke or death from any cause, whichever came first [1].
  • Funding: the Swiss National Science Foundation [1].

Participants were followed for up to four years (48 months), with the main noninferiority test at two years [1][2][6]. Because everyone was already taking a statin at the start, the trial tested the effect of stopping, not of starting, a statin late in life [1].

Why was stopping statins after 70 an open question?

Because evidence on statins for primary prevention in the oldest adults is thin: the US Preventive Services Task Force says it is insufficient to judge the benefits and harms of starting a statin at 76 or older [5].

  • Younger adults: the USPSTF recommends a statin for primary prevention in adults aged 40 to 75 with at least one risk factor, such as high cholesterol, diabetes, high blood pressure or smoking, and an estimated 10-year cardiovascular risk of 10% or more [5].
  • USPSTF position on older adults: its 2022 recommendation found the current evidence insufficient to assess the balance of benefits and harms of initiating a statin for primary prevention in adults 76 years or older [5].
  • Starting is not the same as stopping: in its response to public comments, the Task Force said its recommendation is about initiating a statin; the page does not set out a recommendation on whether people aged 76 or older already taking one should continue [5].

STREAM is a randomised trial that compares stopping and continuing directly in people already on statins [1]. It is one trial, run in 24 centres in three European countries [2][6].

The NHS, for example, still lists being aged 85 or over among the factors that may put a person at higher risk of cardiovascular disease and lead to a statin being offered [4].

How much did heart risk rise after stopping statins?

The lead investigator, Nicolas Rodondi of the University of Bern, estimated one additional major cardiovascular event or death over two years for every 40 people who stopped statins [2][6]. The AHA summary says this "will require further investigation" [2].

The American College of Cardiology reported that Rodondi "reinforced the need for shared decision-making around statin therapy" given the increase in cardiovascular events after stopping [3]. It also reported that the trial's data and safety monitoring board recommended advising participants in the stopping group to discuss restarting statins with their care team [3].

Rodondi said the findings "provide information for shared decision-making about cautious statin discontinuation when statins are used for primary prevention only," and that more randomised trials of stopping specific drugs are needed [2].

The table below sets out the main results from the paper and the AHA summary.

An older patient's hands and a doctor's hands over a table with a pill bottle, representing shared decision-making about stopping statins
STREAM investigators stress shared decisions between patients and clinicians.

Did people feel better after stopping statins?

No measurable difference was found: in a secondary analysis of patient-centred outcomes, including pain, quality of life, falls and sarcopenia (muscle loss) risk, the two groups did not differ, according to the AHA [2]. TCTMD reported no significant differences in pain at 3 months, falls at 12 months, or quality of life and sarcopenia risk at 24 months [6].

In STREAM, people who stopped did not report less pain or better quality of life over the follow-up than those who continued [2].

  • What statins do: the NHS describes statins as medicines used to lower cholesterol, which can help prevent heart problems and stroke [4].
  • Stopping on your own: the NHS says that stopping statins may affect cholesterol levels and advises talking to a doctor or pharmacist before stopping [4].

Questions about whether to continue a medicine belong in a conversation with the prescriber, who can weigh age, other conditions and personal priorities. Chatbots sometimes overstate or misreport trial results like this one; why that happens is covered in AI Hallucinations Explained: Why Chatbots Make Things Up and How to Get Accurate Answers.

This is not medical advice. Decisions about your own treatment belong with a qualified clinician who knows your history.

A generic clinic desk with a blood pressure cuff, stethoscope and tablet blister strip, accompanying the STREAM trial follow-up of older adults
Participants in STREAM were followed for a median of about two years.

What does STREAM not show?

STREAM does not show that statins are useless in older people, and it does not apply to anyone taking statins after a heart attack, stroke or other cardiovascular disease [1][2]. Its findings are limited to a specific group and a two-year horizon.

  • Secondary prevention excluded: everyone enrolled had no known cardiovascular disease [1].
  • Two-year main result: the noninferiority test was set at two years; longer-term effects of stopping are not settled by this result [1].
  • Multimorbid patients only: participants had at least two chronic conditions, so the trial does not show whether the results apply to healthier people over 70 [1].
  • No specific reason to stop: a TCTMD report says discussant Dinesh Kalra observed that participants had no specific reasons to stop statins, such as limited lifespan or troublesome side effects; the trial does not show what happens for people who do have such reasons [6].
  • Open-label design: participants and their doctors knew which group each person was in, as the paper describes the trial as open-label [1].
  • Three European countries: the trial ran in 24 centres in Switzerland, France and the Netherlands [2][6]

Headlines saying older people "can stop statins safely" leave out the higher event numbers and the trial's own call for shared decisions [1][3]. How regulators and clinicians judge medical evidence in the age of AI tools is discussed in AI in Healthcare: What It Can Do Today, Where It Fails and How It Is Regulated.

STREAM trial: main results (NEJM, 7 November 2026, and AHA summary)
MeasureStopped statinsContinued statinsSource
Participants938942NEJM [1]
Primary-outcome events, median 103 weeks119 (12.7%)87 (9.2%)NEJM [1]
At least one serious adverse event43.0%39.8%NEJM [1]
Difference in event-free time at 2 years−2.0 weeks (margin −5.2)ReferenceNEJM [1]

Common mistakes

  • Reading 'noninferior' as 'no extra risk'

    Fix: Events were higher after stopping; the difference stayed inside a preset margin [1].

  • Applying STREAM after a heart attack or stroke

    Fix: The trial only enrolled people without known cardiovascular disease [1].

  • Expecting less muscle pain after stopping

    Fix: No difference in pain, quality of life, falls or sarcopenia risk was found [2][6].

  • Stopping statins without advice

    Fix: The NHS advises talking to a doctor or pharmacist before stopping [4].

  • Generalising to all over-70s

    Fix: Participants had at least two chronic conditions and were followed for about two years [1].

Frequently asked questions

What did the STREAM trial find about stopping statins?

Stopping was noninferior at two years on a preset margin, but events were higher: 12.7% versus 9.2% [1].

Who was in the STREAM trial?

1,880 adults aged 70+ with two or more chronic conditions, taking statins for primary prevention [1].

Why was stopping statins after 70 an open question?

The USPSTF says evidence is insufficient on starting statins at 76 or older, and its recommendation is about initiating, not stopping [5].

How much did heart risk rise after stopping statins?

Investigators estimated one extra major event or death per 40 people stopping over two years [2][6].

Did people feel better after stopping statins?

No difference in pain, quality of life, falls or sarcopenia (muscle loss) risk was found [2][6].

What does STREAM not show?

It does not apply to people with cardiovascular disease or show statins are useless [1][2].

Glossary

Statin
A medicine that lowers the amount of cholesterol the body makes.
Primary prevention
Treatment to prevent a first heart attack or stroke in people without known cardiovascular disease.
Noninferiority trial
A trial testing whether one approach is not worse than another by more than a preset margin.
Open-label
A trial design in which participants and doctors know which treatment group each person is in.
Deprescribing
The planned reduction or stopping of a medicine that may no longer be appropriate.
Multimorbidity
Having two or more long-term health conditions at the same time.

Sources

  1. Discontinuing Statins in Older Adults without Cardiovascular Disease (STREAM) New England Journal of Medicine · 2026-11-07
  2. Late-breaking trials challenge conventional treatments to cardiovascular disease American Heart Association Scientific Sessions · 2026-11-08
  3. STREAM, eZ-PAVE Add New Insights Into Statin Therapy Treatment American College of Cardiology · 2026-11-07
  4. Statins NHS · 2026-05-05
  5. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication US Preventive Services Task Force · 2022-08-23
  6. Elderly Patients on Statins for Primary Prevention Can Stop, but It’s Not Risk Free: STREAM TCTMD (Cardiovascular Research Foundation) · 2026-11-08
Share this guide Telegram WhatsApp X
0 likes

Comments

Top comments

About the Pouyam Team Editorial policy

On Pouyam

Explore Pouyam

Guides are one corner of Pouyam. Here is where to go next.

Quick navigation